Lion Biotechnologies, Inc. (NASDAQ:IOVA) – Stock analysts at Oppenheimer Holdings lifted their FY2017 earnings per share (EPS) estimates for shares of Lion Biotechnologies in a report issued on Tuesday. Oppenheimer Holdings analyst M. Breidenbach now forecasts that the biotechnology company will earn ($1.40) per share for the year, up from their prior forecast of ($1.45). Oppenheimer Holdings has a “Buy” rating and a $13.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Lion Biotechnologies’ Q4 2017 earnings at ($0.33) EPS, Q1 2018 earnings at ($0.33) EPS, Q2 2018 earnings at ($0.33) EPS, Q3 2018 earnings at ($0.34) EPS, Q4 2018 earnings at ($0.32) EPS, FY2018 earnings at ($1.33) EPS, FY2019 earnings at ($1.28) EPS, FY2020 earnings at ($1.25) EPS and FY2021 earnings at ($1.12) EPS.

COPYRIGHT VIOLATION NOTICE: This news story was posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/09/29/lion-biotechnologies-inc-expected-to-earn-fy2017-earnings-of-1-40-per-share-iova.html.

Other analysts also recently issued reports about the company. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Lion Biotechnologies in a research report on Wednesday, June 7th. Cowen and Company restated a “buy” rating on shares of Lion Biotechnologies in a research report on Tuesday, June 6th. Zacks Investment Research upgraded Lion Biotechnologies from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a research report on Tuesday, July 18th. Chardan Capital restated a “buy” rating and set a $20.00 price objective on shares of Lion Biotechnologies in a research report on Friday, September 1st. Finally, Jefferies Group LLC restated a “buy” rating and set a $11.00 price objective on shares of Lion Biotechnologies in a research report on Tuesday, September 5th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $13.88.

Lion Biotechnologies (NASDAQ IOVA) opened at 7.90 on Thursday. Lion Biotechnologies has a one year low of $4.45 and a one year high of $8.60. The firm’s 50 day moving average price is $5.61 and its 200-day moving average price is $6.42. The company’s market capitalization is $555.95 million.

Institutional investors and hedge funds have recently modified their holdings of the business. Legal & General Group Plc acquired a new position in Lion Biotechnologies in the 2nd quarter worth about $103,000. Parametric Portfolio Associates LLC acquired a new position in Lion Biotechnologies in the 2nd quarter worth about $125,000. People s United Financial Inc. acquired a new position in Lion Biotechnologies in the 2nd quarter worth about $143,000. Voya Investment Management LLC acquired a new position in Lion Biotechnologies in the 2nd quarter worth about $208,000. Finally, ProShare Advisors LLC acquired a new position in Lion Biotechnologies in the 2nd quarter worth about $270,000. 76.00% of the stock is owned by institutional investors and hedge funds.

Lion Biotechnologies Company Profile

Iovance Biotherapeutics, Inc, formerly Lion Biotechnologies, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company’s lead program is an adoptive cell therapy utilizing tumor-infiltrating lymphocytes, which are T cells derived from patients’ tumors, for the treatment of metastatic melanoma.

Earnings History and Estimates for Lion Biotechnologies (NASDAQ:IOVA)

Receive News & Ratings for Lion Biotechnologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lion Biotechnologies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.